Penpulimab, identified by the distinct CAS number 2350298-92-7, represents a cutting-edge medicinal antibody currently undergoing research for its potential in tumor treatment. This biologic molecule is designed to target a precise process involved in tumor development. Early data suggest it exhibits encouraging efficacy and is currently studied in

Idacta mAb INT-001 represents an promising clinical method for treating selected blood-related malignancies. This antibody demonstrates a unique mechanism of action, mainly interacting with CD38, the membrane molecule found widely on various hematopoietic populations. Ongoing clinical research are evaluate its safety and efficacy in individuals wit

The arrival of amivantamab offers a important advance for patients battling cancers featuring c-MET aberration. This innovative antibody, a precise blocker of multiple MET kinase and also human epidermal growth factor receptor 2 (HER2), demonstrated encouraging efficacy in clinical trials, particularly in patients whose tumors display exhibitable c